ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) (ELEVATE) (NCT04883905)
Principal Investigator: Dr. Danielle Nance
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Prospective, Observational , Multicenter Study of Effectiveness of Efanesoctocog Alfa on Long-term Joint Health in Patients With Hemophilia A (NCT05911763)
Principal Investigator: Dr. Danielle Nance
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Glioblastoma

A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer (NCT05256290)
Principal Investigator: Jiaxin Niu
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center 

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (NCT06312176)
Principal Investigator: Hung Khong
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center 

Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (NCT06492616)
Principal Investigator: Hung Khong
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center 

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (NCT06380751) 
Principal Investigator: Qing Zhao
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center 

Prospective comparison of MRI versus contrast enhanced mammography prior to surgery in breast cancer patients: a randomized controlled trial (NCT04770714) 
Principal Investigator: Michael Morris
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center and Banner MD Anderson Cancer Center at Banner - University Medical Center Phoenix

Inflammatory Breast Cancer (IBC) Registry (NCT00477100) 
Principal Investigators: Hung Khong (AZ), Esther Mondo (NoCo)
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center at Banner Boswell Medical Center, Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center 

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (NCT03488693)
Principal Investigator: Supriya Jain
Location: Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (NCT05894239)
Principal Investigator: Qing Zhao
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer (NCT05508906)
Principal Investigators: Hung Khong 
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients With Metastatic Breast Cancer With Expansion in Metastatic Triple Negative Breast Cancer (NCT04115306)
Principal Investigators: Hung Khong 
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Thyroid

A Phase 1, Open-label Study of BDTX-4933 in Patients With BRAF and Other Select RAS/MAPK Mutation-Positive Neoplasms (NCT05786924)
Principal Investigator: Jiaxin Niu
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center 

Colorectal Cancer

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer (NCT05961709)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (NCT06662786)
Principal Investigator: Zachary Yeung
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Gastrointestinal Cancers

Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors (NCT05155332)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Gastric Cancer

A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma) (NCT06356311)
Principal Investigator: Christina Gomez
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer (NCT06532006)
Principal Investigator: Francis Hall
Location: Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center 

Colorectal, Pancreatic, Rectal, Esophageal

An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing (NCT04981119)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Pancreatic Cancer

RASolute 302: a Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 Versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06625320)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (NCT05040360)
Principal Investigator: Zachary Yeung
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Bladder Cancer 

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2 (NCT04879329)
Principal Investigator: Alex Bowman
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States (NCT06026332)
Principal Investigator: Joseph Mashni
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC) (NCT05024773)
Principal Investigator: Joseph Mashni
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05014139)
Principal Investigator: Chinedu Mmeje
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Prostate Cancer

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge (NCT06764485)
Principal Investigator: Alex Bowman
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION (NCT03972657)
Principal Investigator: Alex Bowman
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (NCT05050084)
Principal Investigator: Mark Dziemianowicz (CO), Yerko Borghero (AZ)
Location: Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer (NCT03678025)
Principal Investigator: Chinedu Mmeje (AZ), Supriya Jain (NoCo)
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) (NCT05053152)
Principal Investigator: Mark Dziemianowicz 
Locations: Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center

Cervical Cancer 

Molecular and microbial drivers of cervical cancer progression and response to therapy
Principal Investigator: Gary Walker (AZ), Robin Lacour (CO)
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center

Endometrial Cancer

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma (NCT05256225)
Principal Investigator: Robin Lacour
Locations: Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center

Squamous Cell Carcinoma

A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma (NCT05323253)
Principal Investigator: Michael Samuels
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) (NCT06064877)
Principal Investigator: Saba Radhi
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center 

Xerostomia Caused by Radiotherapy

A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia (NCT05926765)
Principal Investigator: Gary Walker
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (NCT06479135)
Principal Investigator: Mark Faber
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT04067336) 
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Acute Myeloid Leukemia (AML)

Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy (NCT06384261)
Principal Investigator: Ambuga Badari
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia(NCT06001788)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study Brief Summary (NCT05546580)
Principal Investigator: Rajneesh Nath
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT (NCT05429632)
Principal Investigator: Rajneesh Nath
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Chronic Myeloid Leukemia

A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (NCT06163430)
Principal Investigator: Mark Faber
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Lung Cancer

Ambulation to Improve Recovery With Wearable TECHnology (AIRTECH) Study (NCT04783168)
Principal Investigator: Elbert Kuo
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Non-Small Cell Lung Cancer

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (HARMONi-7) (NCT06767514)
Principal Investigator: Emily Simons
Location: Banner MD Anderson Cancer Center at North Colorado Medical Center

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (NCT06623422)
Principal Investigator: Jiaxin Niu (AZ) and Lin Hao (NoCo)
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center

A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer (NCT05256290)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06497556)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression (NCT06119581) 
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06497556) 
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center and Banner MD Anderson Cancer Center at Banner - University Medical Center Phoenix

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (NCT06767514) 
Principal Investigator: Todd Erickson
Location: Banner MD Anderson Cancer Center at Banner - University Medical Center Phoenix

Small Cell Lung Cancer

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (NCT04155034)
Principal Investigator: Supriya Jain
Location: Banner MD Anderson Cancer Center Radiation Oncology Clinic at Banner North Colorado Medical Center – Loveland Campus and Banner MD Anderson Cancer Center at North Colorado Medical Center

A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma (NCT06500273)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy (NCT05332054)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center 

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (NCT04989803) 
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (NCT04792489) 
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (NCT04637763)
Principal Investigator: Rajneesh Nath
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23) (NCT05605899)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center 

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies (NCT05544019)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma (NCT06246916)
Principal Investigator: Fade Mahmoud
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment (NCT06264180)
Principal Investigator: Fade Mahmoud
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Decision Dx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
Principal Investigator: Mark Gimbel
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma (NCT06014086)
Principal Investigator: Mark Gimbel
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (02.18 MelMarT-II) (NCT03860883)
Principal Investigator: Mark Gimbel
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) (NCT06297226)
Principal Investigator: Ambuga Badari
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma (NCT06413498)
Principal Investigator: Sumit Madan
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed And/or Refractory Multiple Myeloma (NCT06433947)
Principal Investigator: Sumit Madan
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION (NCT05317416)
Principal Investigator: Sumit Madan
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression (NCT06682793)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (NCT06051695)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation (NCT05877599) 
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts (NCT06241456) 
Principal Investigator: Hung Khong
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors (NCT05989724)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors (NCT05599984)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients With Relapsed or Refractory Advanced Solid Tumors (NCT06014502) 
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial (NCT06745024) 
Principal Investigator: Mark Dziemianowicz
Location: Banner MD Anderson Cancer Center at North Colorado Medical Center

A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP) (NCT06367972) 
Principal Investigator: Supriya Jain
Location: Banner MD Anderson Cancer Center at North Colorado Medical Center